arrow
T

Thomas M. Schmitt

fred hutchinson cancer center
H指数:32
被引数:5,651

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma

将工程化自体T细胞重编程以克服 Merkel细胞癌患者的耐药性

2026-09-090
PRE
A CD8αβ co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligands

一种经过修饰以包含细胞内CD28信号尾部的CD8αβ共受体,能够独立于实体瘤相关共刺激配体而增强TCR工程化T细胞的功能。

2026-01-030
OA
Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition

胰腺癌特异性隐蔽抗原是T细胞识别的靶点

SCIENCE
IF45.8
2025-05-080
PRE
AFNT-212: A TRAC-knocked-in KRASG12D-specific TCR-T cell product enhanced with CD8αß and a chimeric cytokine receptor for treatment of solid cancers
2024-03-220
PRE
Non-viral engineered T cell therapy specific for the hotspot mutation p53 R175H that integrates signal 1 (TCR), signal 2 ( co-stimulation) and signal 3 (cytokine) and co-opts FasL-dependent apoptosis to achieve a coordinated antitumor CD4/8 T cell response
2024-03-220
PRE
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001
2024-03-196
OAAI
Large libraries of single-chain trimer peptide-MHCs enable antigen-specific CD8+T cell discovery and analysis
2023-05-165
OAAI
Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency
2022-02-0916
OA
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant
2019-06-24248
OAAI